1

March 22, 2017

Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma Announces New Chief Executive Officer at
Boston Biomedical, Inc. and Establishment of Global Head of Oncology
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada)
today announced the following change of chief executive officer at its U.S. consolidated subsidiary
Boston Biomedical, Inc. and establishment of Global Head of Oncology, effective April 24,2017.
I.
Change of Chief Executive Officer at Boston Biomedical, Inc. (effective April 24, 2017)
(1) Reason for change
Retirement of current Chief Executive Officer Chiang J. Li at the expiration of his term of office
and appointment of new Chief Executive Officer

(2) Details of appointment changes
Name
New Position
Current position
Patricia S. Andrews
CEO, Boston Biomedical, Inc.
Executive Vice President and COO , Boston Biomedical Pharma, Inc.
*
１

Chiang J. Li
－
*2

President, CEO and CMO, Boston
Biomedical, Inc.

* 1 As announced on December 21, 2016, Boston Biomedical Pharma, Inc. will merge with
Boston Biomedical, Inc., effective April 1, 2017 (surviving company: Boston Biomedical,
Inc.).
* 2 Chiang J. Li will retire from the position of Head of Global Oncology for Sumitomo
Dainippon Pharma Group as well as from Boston Biomedical, Inc., and will be appointed
Senior Special Oncology Advisor of Sumitomo Dainippon Pharma, Co. Ltd., effective May 1,
where he will provide advice on the instructions of the president of Sumitomo Dainippon
Pharma.

II. Establishment of Global Head of Oncology (effective April 24, 2017)
With the retirement of Chiang J. Li, the new position of Global Head of Oncology will be
established, effective April 24, and Kazuo Koshiya will be appointed to this position. Effective
on the same date, Yasushi Matsuki will assume the position of Senior Director of DSP Cancer
Institute.
Global Head of Oncology will take the lead in overall oncology business of Sumitomo
Dainippon Group. Sumitomo Dainippon Pharma Group positions oncology as one of its focus

2

therapeutic areas. Under the leadership of Global Head of Oncology, Sumitomo Dainippon
Pharma (DSP Cancer Institute, Oncology Clinical Development Unit), Boston Biomedical, Inc.
and Tolero Pharmaceuticals, Inc. (Headquarters: Lehi, UT, U.S., CEO: David J. Bearss) will
collaborate on R&D with the aims of continuously creating innovative compounds and
accelerating filings and approvals of development pipeline in order for oncology products to
contribute to company performance as early as possible.

The positions of Kazuo Koshiya and Yasushi Matsuki as of April 24 will be as follows.
(Reference
：
Oncology pipeline)

The products in Sumitomo Dainippon Pharma Group’s oncology pipeline that are being
developed with a view to early regulatory filing are the cancer stemness inhibitors napabucasin
and amcasertib, the cyclin-dependent kinase 9 inhibitor alvocidib, and the WT1 cancer peptide
vaccine DSP-7888.

As already announced, napabucasin is currently in multiple phase 3 studies. We are aiming at
regulatory filings for the indications of gastric cancer and gastroesophageal junction
adenocarcinoma (combination therapy) in the U.S.A. and Japan in fiscal year 2018. Regarding
alvocidib, a phase 2 study is being conducted in patients who have tested positive for acute
myeloid leukemia (AML) biomarkers in the U.S.A. and the group aims to file an application for
approval of this indication in fiscal year 2018 at the earliest.
Contact:
Public Relations/Investor Relations
Sumitomo Dainippon Pharma Co., Ltd.
TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)
Name
Position as of April 24
Current position
Kazuo
Koshiya
Senior Executive Officer
Boston Biomedical, Inc.;
Global Oncology Office; Oncology
Clinical Development Unit; Oncology
Strategy Unit; DSP Cancer Institute;
Global Head of Oncology
Senior Executive Officer
Boston Biomedical Pharma, Inc.;
Global Oncology Office; Oncology
Clinical Development Unit; Oncology
Strategy Unit; Head of Global
Oncology Office
Yasushi
Matsuki

Senior Director, Global Oncology
Office,
Senior Director, DSP Cancer Institute
Senior Director, Global Oncology
Office

3